Product Details
Synonym
ACE-2, ACEH, ACE2
Source
Human ACE2, Mouse IgG1 Fc Tag (AC2-H5205) is expressed from human 293 cells (HEK293). It contains AA Gln 18 - Ser 740 (Accession # Q9BYF1-1).
Predicted N-terminus: Gln 18
Request for sequenceMolecular Characterization

Other Tags and Version Biotin & Other Labeled Version
This protein carries a mouse IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 109.8 kDa. The protein migrates as 125-150 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Purity
>95% as determined by SDS-PAGE.
Formulation
Supplied as 0.2 μm filtered solution in 50 mM Tris, 150 mM NaCl, Arginine, pH7.5 with glycerol as protectant.
Contact us for customized product form or formulation.
Shipping
This product is supplied and shipped with dry ice, please inquire the shipping cost.
Storage
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- The product MUST be stored at -70°C or lower upon receipt;
- -70°C for 3 months under sterile conditions.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE

Human ACE2, Mouse IgG1 Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
SEC-MALS

The purity of Human ACE2, Mouse IgG1 Fc Tag (Cat. No. AC2-H5205) is more than 85% and the molecular weight of this protein is around 240-255 kDa verified by SEC-MALS.
Report
Bioactivity-ELISA

Immobilized SARS-CoV-2 S protein RBD, His Tag (Cat. No. SPD-C52H3) at 1 μg/mL (100 μL/well) can bind Human ACE2, Mouse IgG1 Fc Tag (Cat. No. AC2-H5205) with a linear range of 0.4-6 ng/mL (QC tested).
Protocol
Immobilized Human ACE2, Mouse IgG1 Fc Tag (Cat. No. AC2-H5205) at 1 μg/mL (100 μL/well) can bind SARS-CoV-2 S1 protein, Fc Tag (Cat. No. S1N-C5255) with a linear range of 1-20 ng/mL (Routinely tested).
Protocol
Customer Reviews Writing Reviews

Background
Recent Advances
- English Name:
Angiotensin-converting enzyme 2
- Category:
- Approved Drugs:
0 Details
- Drugs in Clinical Trials:
5 Details
- Highest Development Stage:
Phase 2 Clinical
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
















